Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
about
Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
P2860
Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Lack of objective response of ...... after failure of azacitidine.
@en
Lack of objective response of ...... after failure of azacitidine.
@nl
type
label
Lack of objective response of ...... after failure of azacitidine.
@en
Lack of objective response of ...... after failure of azacitidine.
@nl
prefLabel
Lack of objective response of ...... after failure of azacitidine.
@en
Lack of objective response of ...... after failure of azacitidine.
@nl
P2093
P2860
P1433
P1476
Lack of objective response of ...... after failure of azacitidine.
@en
P2093
Bhavana Bhatnagar
Dan P Zandberg
Emily J Vannorsdall
Maria R Baer
Michael L Tidwell
Vu H Duong
P2860
P304
P356
10.3109/10428194.2014.966708
P577
2014-11-03T00:00:00Z